ABN 501
Alternative Names: Anti-claudin 3 antibody - Abion; Anti-CLDN3 monoclonal antibody - Abion; α-ABN501Latest Information Update: 30 Jun 2025
At a glance
- Originator Abion
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from preclinical trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 13 Jul 2023 Abion plans a phase I trial for Solid tumors (Monotherapy) in South Korea in 2023 (Abion pipeline, July 2023)